Are you an accomplished asset manager looking to grow your personal wealth beyond $1 billion? If not, there are valuable lessons to be learned from those who have achieved this milestone.
Fortunately, the Securities and Exchange Commission requires managers with over $100 million to disclose their trades every quarter, providing insights for everyday investors like us.
A recent review of Baker Bros. Advisors’ latest disclosures reveals that billionaire brothers Julian and Felix have invested in over a dozen biopharmaceutical stocks in the first quarter of 2024.
Among their notable investments are AbCellera Biologics (NASDAQ: ABCL) and Fate Therapeutics (NASDAQ: FATE), despite both stocks experiencing a significant decline since the beginning of the year.
Considering the expertise of billionaire investors in the biopharmaceutical sector, following their lead could potentially benefit your portfolio. Here’s why…
2024-07-21 04:37:00
Original post available on finance.yahoo.com
